<DOC>
	<DOCNO>NCT00629031</DOCNO>
	<brief_summary>It randomize , double-blind , multi-center , two-arm study intend assess safety efficacy three different doses/dose regimen paromomycin administer intramuscularly follow : 11 mg/kg/day 14 day 11 mg/kg/day 21 day treatment visceral leishmaniasis ( VL ) India .</brief_summary>
	<brief_title>An Open Lable Randomised Study Assess Safety Efficacy Short Course Paromomycin Visceral Leishmaniasis</brief_title>
	<detailed_description>Paromomycin administer dose 11 mg/kg/day IM 21 day previously demonstrate iOWH WHO effective amphotericin B administer IV dose 1 mg/kg/every day total total 15 dos 30 day treatment VL Bihar , India ( protocol VLPM01 ) recently complete study ( 94.6 % vs. 98.8 % subject disease free 6 month , respectively ) . This new study conduct determine whether similar good efficacy safety IM paromomycin achieve short duration treatment ( 14 day rather 21 day ) administer short duration ( 14 day rather 21 day ) regimen study previous trial . This short duration study compare initial final cure ( response treatment ) rate subject VL receive paromomycin follow dos dose regimen : - Group A : paromomycin 11 mg/kg/day IM 14 day - Group B : paromomycin 11 mg/kg/day IM 21 day Because compliance generally improve short duration therapy , good treatment compliance decrease probability emergence drug-resistant disease , administration high daily dos paromomycin short time may improve efficacy without produce unacceptable toxicity . In addition , treatment regimen short duration would cost less easy administer . The current study design explore different dos dose regimen IM paromomycin determine dose dose regimen recommend first-line therapy treatment VL , maintain efficacy safety .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>Children adult , male female , age 5 55 year , inclusive , provide write informed consent . New relapse VL prior VL treatment failure regimen contain Paromomycin AmBisomeÂ® . The diagnosis VL must confirm parasitepositive splenic aspirate . LFT great 3 time ULN ( AST , ALT , S.Bilirubin , Alkaline Phosphatase , Hb &lt; 4 gm/dl . Platelet &lt; 40,000/ mm3 Prothrombin Time &gt; 3 Sec . long Control . Creatinine &gt; 3 time Normal Value For Male ( 0.6 1.1 ) Normal Value For Female ( 0.5 0.9 ) Absolute Leucocyte count &lt; 1,000 HIV infection Abnormal audiometric and/or vestibular dysfunction History renal dysfunction Other severe medical condition History allergy hypersensitivity aminoglycosides Treatment parenteral aminoglycoside within 28 day prior randomisation Previous VL treatment within past 14 day Previous treatment VL paromomycin time Pregnancy , lactation , lack use contraception woman childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Visceral leishmaniasis</keyword>
	<keyword>Paromomycin</keyword>
</DOC>